Get the latest news, insights, and market updates on HRMY (Harmony Biosciences Holdings, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Is Harmony Biosciences (HRMY) Pricing Reflect Future Growth After Recent Mixed Share Performance
If you are looking at Harmony Biosciences Holdings and wondering whether the current share price offers good value, the next few sections will walk through what the numbers are saying about the stock. The share price recently closed at US$38.61, with returns of 3.3% over the past week, a 1.7% decline over the last 30 days, 3.3% year to date, 14.0% over the past year, an 18.6% decline over three years, and a 0.5% decline over five years. Recent attention on Harmony Biosciences has been shaped... Jan 10, 2026 - $HRMY
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Jan 8, 2026 - $HRMY
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
PLYMOUTH MEETING, Pa., January 07, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffrey M. Dayno, M.D., President and Chief Executive Officer, is scheduled to present at the conference on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET. Jan 7, 2026 - $HRMY
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony’s Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collabo Dec 16, 2025 - $HRMY
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
PLYMOUTH MEETING, Pa., December 08, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants with DS along with a favorable benefit-risk profile. Dec 8, 2025 - $HRMY
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors
In November 2025, Harmony Biosciences reported positive pivotal bioequivalence results for its gastro-resistant pitolisant formulation and began a Phase 1 trial of BP1.15205, an investigational orexin 2 receptor agonist for central disorders of hypersomnolence. These developments could extend pitolisant-related exclusivity toward 2044 while adding a new mechanism in orexin agonism, deepening Harmony’s sleep-disorder treatment portfolio. Next, we’ll explore how progress on pitolisant GR’s... Dec 3, 2025 - $HRMY
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound
If you are wondering whether Harmony Biosciences Holdings at around $36 is quietly undervalued or just fairly priced, this piece will walk through whether the current share price lines up with the company’s fundamentals. The stock has climbed 1.3% over the last week and 22.8% over the past month, yet it is only up 3.4% year to date and 3.1% over the last year. It is still sitting well below its 3 year return of -40.0% and 5 year return of -17.0%. Recent attention on Harmony has centered on... Dec 3, 2025 - $HRMY
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial
Harmony Biosciences Holdings (HRMY) just cleared two important scientific milestones: positive bioequivalence data for its gastro resistant pitolisant and first patient dosing in a new orexin 2 agonist trial, sharpening the growth story. See our latest analysis for Harmony Biosciences Holdings. The recent clinical wins seem to be feeding into sentiment, with the stock delivering a roughly mid-twenties 1-month share price return to around 35 dollars. However, the 3-year total shareholder... Dec 3, 2025 - $HRMY
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
PLYMOUTH MEETING, Pa., December 02, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. Dec 2, 2025 - $HRMY
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple